Choline compound (supplement)

CDP-Choline (Citicoline)

CDP-choline (citicoline) releases choline and cytidine after dosing, and the app lists a 56-hour half-life that none of the source texts used here states.1

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

CDP-Choline (Citicoline) after one dose: 50% at ~56 h, 25% at 112 h, 12.5% at 168 h.

Drawn from the half-life in the app's model, ~56 h. The model's figures

1

Overview

Citicoline, also written cytidine 5'-diphosphocholine or CDP-choline, is described in a 2006 review as an intermediate in the making of membrane phospholipids, particularly phosphatidylcholine.1 The app files it as a choline supplement taken by mouth, with a typical dose of 250 to 500 mg/day. The app grades the evidence as moderate. A narrative review by Gareri and colleagues (Clinical Interventions in Aging, 2015) describes citicoline as a water-soluble compound with more than 90% bioavailability.2 The trials described below cover adults aged 50 to 85 with age-associated memory impairment, healthy adolescent males, adults with alcohol use disorder, acute ischaemic stroke and traumatic brain injury, at doses from 250 mg to 4000 mg, and two report company funding (Kyowa Hakko Bio for Nakazaki, Ferrer Grupo for ICTUS) while a third, McGlade, has authors at Kyowa Hakko companies.

No DailyMed drug label for citicoline was identified, so no label supplies the half-life, strength or indications.

Secades and Lorenzo, in a 2006 review from the Medical Department of Grupo Ferrer S.A., write that after oral or parenteral administration citicoline "releases its two main components, cytidine and choline".1 Gareri and colleagues describe exogenous CDP-choline as hydrolyzed, absorbed as cytidine and choline, and "resynthesized in the brain".2 The same 2006 review states that citicoline "has been experimentally shown to increase norepinephrine and dopamine levels in the CNS", and that it improves learning and memory performance in animal models of brain aging; these are experimental findings, not results in the trials below.1 The app's notes describe the mechanism as supporting phosphatidylcholine synthesis and increasing dopamine receptor density. None of the source texts examined mentions dopamine receptors or receptor density. In people given oral citicoline, Wurtman and colleagues (Massachusetts Institute of Technology, Biochemical Pharmacology, 2000) measured plasma choline, cytidine and uridine, and concluded that the circulating substrates involve "uridine and choline, and not cytidine and choline as in rats".3 A 2024 review by Cavalu and colleagues says citicoline "assumes a pivotal role in phosphatidylcholine synthesis" and calls its anti-inflammatory effects a mechanism under study; the review itself says clinical findings "are mixed".4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~56 h
Bioavailability
99%
Typical dose
250–500 mg/day
Route
Oral
Time to peak
~4 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~56 hThe source texts used give no half-life in hours; Gareri and colleagues report that radioactivity from labeled CDP-choline is "eliminated very slowly" and that urinary excretion has a first phase of about 36 hours followed by a slow phase2
Bioavailability99%"Virtually complete" oral absorption in the 2006 review; more than 90% in the 2015 review1,2
Time to peak~4 hPlasma levels "peak in a biphasic manner, at 1 hour after ingestion followed by a second peak at 24 hours postdosing" (2015 review); after single oral doses of 500, 2000 and 4000 mg plasma choline stayed significantly elevated for 5, 8 and 10 hours in 12 adults sampled for 12 hours2,3
RouteOralOral, intravenous and enteral citicoline were used in the trials below9,11

The 2015 review does not say which analyte its "plasma levels" are, and it cites no table of concentrations, so its 1-hour and 24-hour peaks are not a measured time to peak for choline or uridine.2 The app's 4-hour time to peak and 56-hour half-life therefore have no matching figure in the sources used. Sarkar and colleagues (Jadavpur University, Journal of Pharmaceutical and Biomedical Analysis, 2012) measured choline, which they call an active metabolite of citicoline, after a single oral 1000 mg controlled-release tablet in 12 healthy male volunteers, as a bioequivalence study of test and reference tablets.5 The PubMed record gives no concentration, time-to-peak or half-life values. Querying PubMed for "citicoline pharmacokinetics healthy volunteers" returned 2 records, one of which is the Sarkar study.

Deeper analysis: Wurtman 2000, plasma choline and uridine

Wurtman and colleagues gave twelve "mildly hypertensive but otherwise normal fasting subjects" each of four oral treatments in random order: CDP-choline 500, 2000 or 4000 mg, or placebo, on four days, with plasma sampled from 1 to 12 hours.3 Plasma choline rose in a dose-related way in peak values and areas under the curve, and remained significantly elevated for 5, 8 and 10 hours after the three doses.3 Plasma uridine was elevated for 5 to 6 hours, by as much as 70-90% after 500 mg and 100-120% after 2000 mg, with no further increase from 2000 to 4000 mg.3 Plasma cytidine was "not reliably detectable" at any dose, being below 100 nM.3 The app's notes refer to a cytidine fraction with a 56-hour half-life; this trial did not report one, and it detected no plasma cytidine. The record lists grants from the National Center for Research Resources and the National Institute of Mental Health, states no author tie to a citicoline supplier, and gives no limitations section; the sampling window ended at 12 hours.3

4

Human studies

Table 4.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Wurtman and colleagues, Biochemical Pharmacology 20003Randomised, each subject received all four treatments (CDP-choline 500, 2000, 4000 mg and placebo); NIH grants12 mildly hypertensive but otherwise normal fasting subjectsSingle oral doses on four treatment days, plasma sampled for 12 hoursPlasma choline showed dose-related increases and stayed significantly elevated for 5, 8 and 10 hours; plasma uridine rose by as much as 70-90% after 500 mg and 100-120% after 2000 mg, with no further increase at 4000 mg; cytidine not reliably detectable3
Nakazaki and colleagues, Journal of Nutrition 20216Randomised, double-blind, placebo-controlled; sponsored by Kyowa Hakko Bio100 adults aged 50 to 85 with age-associated memory impairment500 mg/d for 12 weeksThe primary outcome was change in Spatial Span, which the paper describes as a tendency toward improvement and does not list among its significant between-group differences; Paired Associate change 0.15 vs 0.06 (P = 0.0025) and composite memory 3.78 vs 0.72 (P = 0.0052) were the significant between-group results, the Paired Associate result labelled a secondary outcome; 6 possibly related adverse events with citicoline against 2 with placebo, none judged serious6
McGlade and colleagues, Journal of Attention Disorders 20197Randomised, placebo-controlled; two authors at Kyowa Hakko Bio and one at Kyowa Hakko USA75 healthy adolescent males250 or 500 mg citicoline (n = 51) or placebo (n = 24) for 28 daysBetter attention (p = 0.02) and psychomotor speed (p = 0.03) than placebo7
Brown and colleagues, Alcoholism: Clinical and Experimental Research 20198Randomised, double-blind, placebo-controlled pilot; NIAAA grant62 adults aged 18 to 75 with alcohol use disorder; 55 analysedCiticoline titrated to 2,000 mg/d for 12 weeksNo between-group differences in alcohol use, craving, cognitive or depressive measures; side effects did not differ (p = .62)8
Dávalos and colleagues, ICTUS, Lancet 20129Randomised, placebo-controlled, sequential; funded by Ferrer Grupo; stopped for futility2298 adults with moderate-to-severe acute ischaemic stroke1000 mg every 12 h intravenously for 3 days then orally, 6 weeks in totalGlobal recovery at 90 days similar (odds ratio 1·03, 95% CI 0·86-1·25; p=0·364); no significant differences in safety variables or adverse event rate9
Zafonte and colleagues, COBRIT, JAMA 201210,11Phase 3, double-blind, randomised; NICHD-sponsored; terminated for futility1213 adults with complicated mild, moderate or severe traumatic brain injury at 8 US trauma centres2000 mg/day orally or enterally for 90 daysFavourable Glasgow Outcome Scale-Extended in 35.4% with citicoline and 35.6% with placebo; global odds ratio 0.98 at 90 days; serious adverse events in 117 of 607 and 117 of 60610,11
Martí-Carvajal and colleagues, Cochrane review 202012Systematic review of randomised trials; all rated high risk of bias; drug companies sponsored six trials4281 people with acute ischemic stroke in 10 trials500 to 2000 mg per day, oral, intravenous or bothAll-cause mortality 17.3% vs 18.5% (RR 0.94, 95% CI 0.83 to 1.07), citicoline vs placebo, in a pooled analysis of eight trials; low-quality evidence12

Querying PubMed for "citicoline randomized placebo-controlled trial" matched 53 records and listed 20, including trials in glaucoma, depression, schizophrenia and bipolar disorder with cocaine dependence that are not described here.

Deeper analysis: Nakazaki 2021, memory in older adults

Nakazaki and colleagues (Kyowa Hakko Bio, Biofortis Innovation Services and Kyowa Hakko USA; Journal of Nutrition, 2021) ran a 12-week trial at Biofortis in Addison, Illinois, registered as NCT03369925, with 426 people screened and 100 randomised 1:1.6 The product was Cognizin, as 250 mg capsules taken as 2 capsules with breakfast, against microcrystalline cellulose placebo.6 The paper states that "The primary outcome variable was the raw change in Spatial Span scores".6 Spatial Span scores went from 4.65 to 4.90 with citicoline and from 4.75 to 4.67 with placebo, and the text reports a significant improvement from baseline in the citicoline group "but not the placebo group".6 The between-group differences the paper reports as significant were for Paired Associates and Composite Memory, which its summary calls secondary outcomes.6 No other test differed between groups: "No additional statistically significant cognitive effects were detected in Monkey Ladder, Digit Span, Interlocking Polygon Task, and Sustained Attention to Response Task".6 The Feature Match task improved within the citicoline group but, in the authors' words, "there was no significant difference between groups".6 Completion was 99 of 100, and one citicoline participant withdrew with a headache judged possibly related to the product.6 The authors list limitations: participants "were specifically screened for AAMI", so the effects "may not be generalizable to young adults", the group was mostly white, and the split was 35:65 males to females.6 They also note the trial "is likely underpowered to assess difference in attention between groups".6 Kyowa Hakko Bio sponsored and "participated in study design, but was not involved in the intervention, data collection, and statistical analysis", and two authors are employees of Kyowa Hakko Bio, one of Kyowa Hakko USA and two of Biofortis Innovation Services.6

Deeper analysis: McGlade 2019, adolescent males

McGlade and colleagues (University of Utah, with authors at Kyowa Hakko Bio and Kyowa Hakko USA) randomised 75 healthy adolescent males to citicoline 250 or 500 mg (n = 51) or placebo (n = 24) and tested them at baseline and after 28 days.7 Measures were the Ruff 2&7 Selective Attention Test, the Finger Tap Test and the Computerized Performance Test, Second Edition.7 The record reports better attention (p = 0.02) and psychomotor speed (p = 0.03) with citicoline, and says higher weight-adjusted dose "significantly predicted" higher accuracy on an attention task (p = 0.01), better signal detectability (p = 0.03) and lower impulsivity (p = 0.01).7 The PubMed record gives no funding statement, no adverse event data and no limitations, and the dose-response result is from within the citicoline group rather than a comparison with placebo.7

Deeper analysis: Brown 2019, alcohol use disorder

Brown and colleagues (University of Texas Southwestern Medical Center, Alcoholism: Clinical and Experimental Research, 2019) randomised 62 adults with alcohol use disorder to citicoline titrated to 2,000 mg/d or placebo for 12 weeks; 55 had at least one post-baseline visit and were analysed.8 On the primary outcome of heavy drinking days there was a main effect of time but "no differences between treatment groups (p = .31)", and craving, memory scores and side effects also did not differ between groups.8 The citicoline group (n=29) was older than the placebo group (n=26) at baseline.8 The authors write: "Because this was a proof-of-concept study the sample size was modest" and "some participants discontinued early or had missing data".8 The study was supported by the National Institute on Alcohol Abuse and Alcoholism (R21AA021777); its conflict statement lists research grants to Dr. Brown from NIH, the Stanley Medical Research Institute and Otsuka and none from a citicoline maker.8

Deeper analysis: ICTUS, acute ischaemic stroke

Dávalos and colleagues (Hospital Universitari Germans Trias i Pujol, Badalona, and the ICTUS investigators; Lancet, 2012) randomised 2298 adults 1:1 within 24 hours of stroke onset at university hospitals in Germany, Portugal and Spain.9 The primary outcome was a global test of recovery at 90 days combining three measures: NIH Stroke Scale of 1 or less, modified Rankin score of 1 or less and Barthel Index of 95 or more.9 The trial "was stopped for futility at the third interim analysis" on data from 2078 patients, and the final analysis of 2298 gave an odds ratio of 1·03 (95% CI 0·86-1·25; p=0·364).9 The authors' interpretation reads "Under the circumstances of the ICTUS trial, citicoline is not efficacious in the treatment of moderate-to-severe acute ischaemic stroke".9 The funder was Ferrer Grupo; the PubMed record lists no author ties and no limitations, but the 2006 review by Secades, an ICTUS author, places him in the Medical Department of Grupo Ferrer S.A., and the Cochrane review lists ICTUS 2012 in a passage on funding bias citing authors who received "consultation fees or honoraria from the trial sponsor".9,1,12

Deeper analysis: COBRIT, traumatic brain injury

Zafonte and colleagues (Massachusetts General Hospital and Harvard Medical School, with 8 US level 1 trauma centres; JAMA, 2012) randomised 1213 patients with complicated mild, moderate or severe traumatic brain injury to a 90-day regimen of citicoline 2000 mg daily or placebo.10 The primary measure was a global statistical test of 9 scales of the TBI-Clinical Trials Network Core Battery at 90 days.10 The groups "did not differ significantly at the 90-day evaluation (global odds ratio [OR], 0.98 [95% CI, 0.83-1.15])", and at 180 days they also did not differ on the primary outcome.10 Neither severity subgroup showed a significant treatment effect, and the conclusion reads: "the use of citicoline compared with placebo for 90 days did not result in improvement in functional and cognitive status".10 The registry entry lists the National Institute of Child Health and Human Development as lead sponsor, status "TERMINATED" and the reason "Trial stopped due to futility.", and reports 117 of 606 on placebo and 117 of 607 on citicoline with serious adverse events.11 The PubMed record lists NICHD grants, with no author ties to a citicoline maker and no limitations section.10

Cochrane review of acute ischemic stroke trials

The Cochrane review by Martí-Carvajal and colleagues searched to 29 January 2020 and included 10 randomised trials with 4281 participants; it rated all trials as having high risk of bias and noted that "Drug companies sponsored six trials".12 In a pooled analysis of eight trials mortality was 17.3% against 18.5% (RR 0.94, 95% CI 0.83 to 1.07) for citicoline against placebo, and in a meta-analysis of three trials serious cardiovascular adverse events were 8.83% against 7.77% (RR 1.04, 95% CI 0.84 to 1.29), both described as low-quality evidence.12 The reviewers conclude that the safety profile "remains unknown" and that adverse events "were poorly reported and harms may have been underestimated".12

5

Doses reported in studies and on labels

No drug label was identified, so no label dose is available. The table lists doses used in the studies above; the app's typical dose is 250 to 500 mg/day.

Table 5.1Doses reported in studies and on labels8 rows
SourceSetting and peopleDose and routeLength
Wurtman 2000312 adults, crossover vs placebo500, 2000 or 4000 mg, oral, single dosePlasma sampled 1 to 12 hours
Sarkar 2012512 healthy male volunteers1000 mg controlled-release tablet, oral, single doseSingle administration
McGlade 2019775 healthy adolescent males; 51 citicoline, 24 placebo250 or 500 mg citicoline28 days
Nakazaki 20216100 adults aged 50 to 85 with age-associated memory impairment; 49 citicoline, 51 placebo500 mg/d, oral capsules12 weeks
Brown 2019862 adults with alcohol use disorder, vs placeboTitrated to 2,000 mg/d, oral12 weeks
ICTUS 201292298 adults with acute ischaemic stroke, vs placebo1000 mg every 12 h intravenously for 3 days, then orally6 weeks in total
COBRIT 201210,111213 adults with traumatic brain injury, vs placebo2000 mg daily, as 1000 mg twice a day, orally or enterally90 days
Cochrane review 20201210 trials in acute ischemic stroke, 4281 participants500 to 2000 mg per day, oral, intravenous or bothVaried by trial

In Nakazaki and colleagues' trial, "No AEs were judged to be serious", and eight adverse events were judged possibly related to a study product, 2 on placebo and 6 on citicoline.6 The 6 on citicoline were increased appetite, weight gain, increased flatulence (2 instances), headache and increased burping, described by the authors as "mild and transient".6 One citicoline participant withdrew because of a headache.6 In the alcohol use disorder trial, the number and type of side effects did not differ between groups.8 In ICTUS, no significant differences were reported in safety variables or adverse event rate.9 In COBRIT the registry lists serious adverse events in 117 of 606 participants on placebo and 117 of 607 on citicoline.11 The Cochrane review describes adverse events in stroke trials as poorly reported and says the safety profile "remains unknown".12 The 2006 review by a Grupo Ferrer author states that "No serious side effects have occurred in any series of patients treated with citicoline".1

7

Bloodwork and markers

The app lists no health markers to monitor for citicoline. In Nakazaki and colleagues' trial, hematology and metabolic panels were taken at baseline and at 12 weeks, with no statistically significant differences in mean values between groups and none outside the normal range.6 In Wurtman and colleagues' trial, plasma choline and uridine were the measured markers; both rose after oral citicoline.3

8

Regulatory and anti-doping status

The WADA 2026 Prohibited List text does not name citicoline, choline or cytidine.13 The list's S0 class covers any pharmacological substance not addressed elsewhere in the list "with no current approval by any governmental regulatory health authority for human therapeutic use".13 The ICTUS paper states that "Citicoline is approved in some countries for the treatment of acute ischaemic stroke", and the COBRIT paper states it is "Approved for use in TBI in 59 countries"; neither is a regulator's document.9,10 No US, EU or Australian regulator document for citicoline was retrieved, and no DailyMed label was identified.

No half-life in hours for oral citicoline appears in the source texts used, so the app's 56 hours stands without a reported figure beside it. The 1-hour and 24-hour plasma peaks in the 2015 review differ from the app's 4-hour time to peak, and the review does not name the analyte.2 The memory and attention results come from two trials (100 and 75 participants) with authors tied to the supplier, in adults aged 50 to 85 with age-associated memory impairment and in adolescent males, the significant between-group memory results in the first were not on its primary outcome, and the alcohol use disorder, stroke and brain injury trials reported no between-group benefit on their primary outcomes.6,7,8,9,10 Cavalu and colleagues write that "further research is imperative to delineate the optimal dosage, treatment duration, and underlying mechanisms".4 The Cochrane review states that the safety profile of citicoline "remains unknown".12

What is the half-life of CDP-choline?

The source texts used give no half-life in hours for oral citicoline, and the app lists about 56 hours. A 2015 review reports that urinary excretion of labeled CDP-choline has a first phase of about 36 hours followed by a slow phase.2

What is the bioavailability of citicoline?

A 2006 review states that oral absorption is virtually complete, and the app lists 99%.1 A 2015 review gives more than 90%.2

How long does citicoline take to peak?

The app lists about 4 hours, while a 2015 review says plasma levels peak at 1 hour after ingestion with a second peak at 24 hours postdosing.2 In 12 adults, plasma choline stayed significantly elevated for 5, 8 and 10 hours after 500, 2000 and 4000 mg.3

Is CDP-choline banned by WADA?

The WADA 2026 Prohibited List text does not name citicoline, choline or cytidine.13 Its S0 class covers substances with no current approval by any governmental regulatory health authority for human therapeutic use, and two trial papers describe citicoline as approved in some countries.13,9

What does CDP-choline break down into?

A 2006 review states that citicoline releases cytidine and choline.1 In 12 adults, plasma uridine rose after oral doses while plasma cytidine was not reliably detectable.3

Did citicoline improve memory in older adults in a trial?

In a 12-week trial of 100 adults aged 50 to 85 with age-associated memory impairment, the primary outcome was change in Spatial Span, for which the paper describes a tendency toward improvement on citicoline, while the Paired Associate change, labelled a secondary outcome, was 0.15 on citicoline against 0.06 on placebo (P = 0.0025).6 The trial was sponsored by Kyowa Hakko Bio, which employs two of its authors.6

Did citicoline work in stroke or brain injury trials?

In ICTUS, with 2298 stroke patients, global recovery was similar in both groups (odds ratio 1·03, 95% CI 0·86-1·25; p=0·364).9 In COBRIT, with 1213 brain injury patients, favourable Glasgow Outcome Scale-Extended rates were 35.4% on citicoline and 35.6% on placebo.10

What side effects were reported with citicoline in trials?

In a 12-week trial, 6 possibly related adverse events occurred on citicoline and 2 on placebo, with none judged serious.6 The alcohol use disorder trial found no difference between groups in number or type of side effects, and the Cochrane review says harms in stroke trials may have been underestimated.8,12

Is citicoline the same as Cognizin?

Cognizin is the name of the citicoline product from Kyowa Hakko Bio used in the Nakazaki trial.6 The app's notes call Cognizin a patented form of citicoline.

12

References

  1. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006. PMID 17171187
  2. Gareri P, et al. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clin Interv Aging 2015. PMC4562749
  3. Wurtman RJ, et al. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol 2000. PMID 10974208
  4. Cavalu S, et al. Unveiling citicoline's mechanisms and clinical relevance in the treatment of neuroinflammatory disorders. FASEB J 2024. PMID 39221499
  5. Sarkar AK, et al. A rapid LC-ESI-MS/MS method for the quantitation of choline, an active metabolite of citicoline: application to in vivo pharmacokinetic and bioequivalence study in Indian healthy male volunteers. J Pharm Biomed Anal 2012. PMID 22951317
  6. Nakazaki E, et al. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Nutr 2021. PMC8349115
  7. McGlade E, et al. The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. J Atten Disord 2019. PMID 26179181
  8. Brown ES, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline in Patients with Alcohol Use Disorder. Alcohol Clin Exp Res 2019. PMC6370505
  9. Dávalos A, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012. PMID 22691567
  10. Zafonte RD, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA 2012. PMID 23168823
  11. ClinicalTrials.gov. NCT00545662. Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT). NICHD, results posted 2012. NCT00545662
  12. Martí-Carvajal AJ, et al. Citicoline for treating people with acute ischemic stroke. Cochrane Database Syst Rev 2020. PMC8406786
  13. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list